Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

Withdrawn before enrolling · Not applicable

Conditions studied: Histologically-confirmed Malignancies

In brief

The purpose of this study is to see if PET/CT scans that use a radioactive substance called \[18F\] fluorothymidine (FLT), can detect and monitor changes in the tumor. Radioactive substances are used with PET/CT scans to "see" cancer cells, and are also called radiotracers. FLT is a new radiotracer that has been given to people in prior studies. FLT PET/CT is an experimental scan unlike FDG (fluorodeoxyglucose) PET scan which is a standard clinical scan and is commonly used. The investigators would like to know if there is any evidence of early treatment response by obtaining FLTPET/ CT scans before and after treatment.

Key facts

Study ID

NCT02139150

Run by

Memorial Sloan Kettering Cancer Center

People needed

0

Starts

2014-05-01

Expected to finish

2020-05-01

Last updated by the study team

2019-09-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically-confirmed (confirmation done at MSKCC) malignancies.
• Patients who have consented to a therapeutic protocol for the treatment of their cancer.
• Patients must be ≥ 18 years old.

You may not qualify if…

• Patients who cannot undergo PET/CT scanning (i.e. because of weight limits, claustrophobia).
• Women who are pregnant or breast-feeding.

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.